{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:16:26Z","timestamp":1770462986509,"version":"3.49.0"},"reference-count":5,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,4,9]],"date-time":"2023-04-09T00:00:00Z","timestamp":1680998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Respirology Case Reports"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>An 83\u2010year\u2010old woman with RET fusion\u2010positive advanced lung adenocarcinoma was administered selpercatinib 320\u2009mg\/day. Despite the shrinking of the tumour, fever, fatigue, and anorexia developed on day 17. Selpercatinib administration was interrupted. On day 21, elevated blood aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were observed. On day 28, AST and ALT levels increased to demonstrate Grade 4 in CTCAE Ver.5. The patient received a glycyrrhizin\u2010compounding agent and steroid treatment, and AST and ALT levels gradually decreased. On day 63, selpercatinib 160\u2009mg\/day was restarted after improvement of the hepatic disorder. Since then, selpercatinib was continued without any severe adverse events. Selpercatinib is a reasonable treatment option for RET fusion\u2010positive advanced non\u2010small cell lung cancer even in older patients. However, old age may be a risk factor for adverse events including hepatic disorders. For safe treatment in such patients, careful follow\u2010up is required.<\/jats:p>","DOI":"10.1002\/rcr2.1136","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T05:34:28Z","timestamp":1681104868000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An 83\u2010year\u2010old patient with <scp>RET<\/scp> fusion\u2010positive non\u2010small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8687-1437","authenticated-orcid":false,"given":"Kazuhisa","family":"Nakashima","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology &amp; Respiratory Medicine Shimane University Faculty of Medicine  Izumo Shimane Japan"},{"name":"Department of Respiratory Medicine National Hospital Organization Hamada Medical Center  Hamada Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5945-6641","authenticated-orcid":false,"given":"Yuki","family":"Mitarai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology &amp; Respiratory Medicine Shimane University Faculty of Medicine  Izumo Shimane Japan"},{"name":"Department of Respiratory Medicine National Hospital Organization Hamada Medical Center  Hamada Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology &amp; Respiratory Medicine Shimane University Faculty of Medicine  Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology &amp; Respiratory Medicine Shimane University Faculty of Medicine  Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takae","family":"Okuno","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology &amp; Respiratory Medicine Shimane University Faculty of Medicine  Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8295-1296","authenticated-orcid":false,"given":"Tamio","family":"Okimoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology &amp; Respiratory Medicine Shimane University Faculty of Medicine  Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Medicine National Hospital Organization Hamada Medical Center  Hamada Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yanagawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine National Hospital Organization Hamada Medical Center  Hamada Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4260-2849","authenticated-orcid":false,"given":"Yukari","family":"Tsubata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology &amp; Respiratory Medicine Shimane University Faculty of Medicine  Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Isobe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology &amp; Respiratory Medicine Shimane University Faculty of Medicine  Izumo Shimane Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,4,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909530"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12941"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005653"},{"key":"e_1_2_9_5_1","unstructured":"The Japanese Lung Cancer Society.Guidelines 2022 for non\u2010small cell lung cancer stages IV.https:\/\/www.haigan.gr.jp\/guideline\/2022\/"},{"key":"e_1_2_9_6_1","unstructured":"National Cancer Center Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) Common Toxicity Criteria (CTC).https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"}],"container-title":["Respirology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rcr2.1136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T08:39:06Z","timestamp":1692693546000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/rcr2.1136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,9]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/rcr2.1136"],"URL":"https:\/\/doi.org\/10.1002\/rcr2.1136","archive":["Portico"],"relation":{},"ISSN":["2051-3380","2051-3380"],"issn-type":[{"value":"2051-3380","type":"print"},{"value":"2051-3380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,9]]},"assertion":[{"value":"2023-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01136"}}